Lupus erythematosus
☆ I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
Ko te ahua o te erythema paku papura.
Ko te ponana pūrerehua ka puta ki te mata.
References
Ko te tautuhi me te whakarōpū i te cutaneous lupus erythematosus (CLE) he wero tātaritanga, he wehewehe mai i te systemic lupus erythematosus me te whakauru kiri. Ko nga rangahau o tata nei ka whakamarama i nga ahuatanga o te ira, te taiao, me te mate mate kei raro i te CLE. Ko te whakaurunga raau taero kua puta ake ko tetahi o nga tino whakaohooho mo CLE. Ko te maimoatanga ka uru ki nga whakamaarama maataki me te punaha, tae atu ki nga koiora whaihua (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059) , me te whakaatu i te kaha ki nga whakamatautau haumanu.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) ka hipoki i nga momo take kiri, ka hono etahi ki nga raru hauora whanui. Kua wehewehea ki nga momo rereke, penei i te acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) . Kei roto i te CCLE te discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Ko te Lupus erythematosus he roopu mate autoimmune ka pa ki nga wahanga rereke o te tinana. Ko etahi momo, penei i te systemic lupus erythematosus (SLE) , ka pa ki nga whekau maha, ko etahi, penei i te cutaneous lupus erythematosus (CLE) , ka pa te nuinga ki te kiri. Ka whakarōpūhia e matou nga momo momo CLE i runga i te ranunga o nga tohu haumanu, te tirotiro kiko, me nga whakamatautau toto, engari he maha nga rereketanga i waenga i nga tangata takitahi. He maha nga wa ka tupu nga raruraru kiri na runga i nga take penei i te rongo ki te ra, te kai paipa, etahi rongoa ranei.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Ko te take o lupus erythematosus kaore i te marama. I roto i nga mahanga rite, ki te pangia tetahi he 24% te tupono ka pa ano tetahi. Ko nga homoni wahine, te ra, te kai paipa, te ngoikore o te huaora D, me etahi mate e whakaponohia ana ka piki ake te tupono.
Ko nga maimoatanga pea ko nga NSAID, corticosteroids, immunosuppressants, hydroxychloroquine, me te methotrexate. Ahakoa e whai hua ana nga corticosteroids, ko te whakamahinga mo te wa roa ka puta nga paanga taha.